Cardiovascular prostheses in congenital heart disease by van Slooten, Ymkje
  
 University of Groningen
Cardiovascular prostheses in congenital heart disease
van Slooten, Ymkje
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2014
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
van Slooten, Y. (2014). Cardiovascular prostheses in congenital heart disease. [S.l.]: [S.n.].
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the








Ymkje J. van Slooten










Background Although the thrombo-embolic risk of pulmonary valve replacement (PVR)
with mechanical valves is presumed to be high, recent studies suggest promising short-
and mid-term results. However, large studies reporƟng long-term mortality and valve
related complicaƟons are missing.
Methods We describe valve related complicaƟons in 66 paƟents with a mechanical
pulmonary valve prosthesis implanted between 1987 and 2013.
Results Mean follow-up duraƟon was 5.9 ± 4.8 years (median 4.9). Mean age at Ɵme
of implantaƟon was 35 ± 13 years. The most frequent underlying cardiac diagnosis was
tetralogy of Fallot (77%). Survival aŌer 5 and 10 years was 91% and 81% respecƟvely.
Main cause of death was heart failure. Nine long-term mechanical valve-related
complicaƟons were reported in 8 paƟents (12%): 5 with valve thrombosis (of which
4 in the seƫng of inadequate anƟcoagulaƟon or pregnancy), 1 paƟent with a mix of
pannus and thrombosis, 1 with pannus, and 2 paƟents with 2 major bleeding episodes.
Redo PVR was performed in 6 paƟents. Freedom from redo PVR in survivors aŌer 5 and
10 years was 96% and 89% respecƟvely.
Conclusions Long-term success of PVR using mechanical valve prostheses was limited
because of valve thrombosis (oŌen in the seƫng of pregnancy or incompliance with
anƟcoagulaƟon therapy) and bleeding complicaƟons. Performance of mechanical valve
prostheses may improve when valve thrombosis is prevented by paƟent selecƟon,
avoiding mechanical valves in paƟents at increased risk of valve thrombosis, and by


















Many paƟents with right-sided congenital heart disease require a pulmonary valve
replacement (PVR) [1,2]. Most centers prefer biological valve prostheses like
allograŌs (homograŌs) in the pulmonary posiƟon as the risk of thrombosis is
low and no anƟcoagulaƟon is needed while deterioraƟon rate is lower than in
leŌ-sided bioprostheses. UlƟmately however, progression of prosthesis dysfuncƟonwill
inevitably lead to repeat PVR. Five percent of corrected Tetralogy of Fallot (ToF) paƟents
with an allograŌ in the pulmonary posiƟon needs a redo PVR aŌer 5 years due to valve
deterioraƟon and the re-PVR rate increases to 30% at 10 years [3, 4]. Mechanical valve
prosthesesmay be an alternaƟve as they have the advantage of long-term durability [5].
However, mechanical valves in the pulmonary posiƟon are assumed to have a high risk
of thromboembolic complicaƟons.
A previous study from our insƟtuƟon [6] as well as other recent studies [7-13] have
indicated that with aggressive anƟcoagulaƟon therapy (InternaƟonal Normalized RaƟo
(INR) 2.5 to 4.5) pulmonary mechanical prostheses may be used with low complicaƟon
rate. However, most of these studies are small or the number of paƟents with longer
follow-up is limited. Data concerning long-term survival as well as thromboembolic and
bleeding complicaƟons are sƟll scarce. This has prevented a wider acceptance of the
use of mechanical prostheses in the pulmonary posiƟon [1,2].
Since our last report [6] the number of paƟentswith amechanical valve prosthesis in our
insƟtuƟon has more than doubled and follow-up duraƟon has increased. The objecƟve




Sixty-six paƟents who underwent PVR with a mechanical valve prosthesis between
February 1987 and April 2013 were idenƟﬁed from the registry of our cardiothoracic
surgery department. This retrospecƟve study was approved by the University Medical
Center Groningen review board. Informed consent was not required according to the
Dutch Medical Research Involving Human Subjects act.
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PVR procedure
The selecƟon of type of prosthesis at Ɵme of surgery was decided by a mulƟdisciplinary
team based on paƟent characterisƟcs and informed paƟent preference. PVRs were
performed through a median sternotomy and subsequent canulaƟon of the ascending
aorta and caval veins. In 15 (22%) procedures cardiopulmonary bypass was established
before sternotomy with canulaƟon of femoral artery and vein. The aorta was
cross-clamped in 19 (28%) paƟents.
AŌer PVR, all paƟents were regularly followed-up by a pediatric or adult cardiologist
with speciﬁc experƟse in congenital heart disease. PaƟents with a mechanical
prosthesis were anƟcoagulated with vitamine K-antagonists (acenocoumarol or
phenprocoumon) aiming for an INR ranging from 2.5 to 4.0 (depending on the Ɵme
period). The level of INR was rouƟnely checked and managed by either the paƟent,
health professionals or specialized laboratories.
Data collecƟon and analysis
Demographic, preoperaƟve, intraoperaƟve and follow-up data were obtained from
medical records. Mortality and morbidity aŌer PVR were reported according to
guidelines [14]. DescripƟve staƟsƟcs were calculated for all measurements as mean
and standard deviaƟon for normally distributed conƟnuous variables, median with
interquarƟle range (IQR) for skewed conƟnuous variables and absolute numbers and
percentages for dichotomous variables. Follow-up was calculated from date of PVR
to date of last contact, redo PVR or death. Survival was calculated using life tables
(cumulaƟve survival proporƟon and standard error (SE)) and presented as Kaplan-Meier
graphs. All staƟsƟcal analyses were performed using the staƟsƟcal soŌware package
IBM SPSS StaƟsƟcs version 20.0 (SPSS Inc., Chicago, IL).
Resultsp
Baseline characterisƟcs
The study populaƟon consisted of 40 males (61%) and 26 females with a mean age of
35 ± 13 years at Ɵme of implantaƟon. Cardiac diagnoses and main indicaƟons for PVR


















Diagnosis Tetralogy of Fallot 51 (77)
Pulmonary valve stenosis 5 (8)
Truncus arteriorus 4 (6)
Pulmonary valve atresia 3 (5)
Ross procedure aŌer endocardiƟs aorƟc valve 2 (3)
Congenitally corrected transposiƟon of the great arteries 1 (2)
Main Pulmonary valve regurgitaƟon 45 (66)
indicaƟon Pulmonary valve stenosis 5 (7)
Mixed pulmonary valve stenosis and regurgitaƟon 6 (9)
Late discovery of Tetralogy of Fallot 1 (2)
DeterioraƟon of previous bioprostheƟc valve 9 (13)
DysfuncƟon of previous mechanical valve 2 (3)
Table 1 - Underlying heart disease and main indicaƟon for PVR.
Underlying cardiac diagnosis in 66 paƟents and indicaƟon for 68 valve replacements.
PVR was mainly performed because of severe pulmonary regurgitaƟon in paƟents
aŌer repair of ToF. All paƟents except one (2%) had previous sternotomies, of which
39 (59%) paƟents had one, 18 (27%) two, 7 (11%) three and 1 (2%) paƟent four
previous sternotomies. Concomitant tricuspid valve annuloplasty was performed in
19 paƟents (29%) that had signiﬁcant tricuspid valve regurgitaƟon in order to prevent
further tricuspid dilataƟon and possible progressive right ventricular dysfuncƟon [2].
At Ɵme of valve implantaƟon 2 (3%) paƟents had a previous implanted internal
cardioverter-deﬁbrillator. During follow-up 13 (20%) addiƟonal paƟents received an
internal cardioverter-deﬁbrillator because of high risk of sudden death.
NYHA class at Ɵme of PVR, available in 58 paƟents, was 3 or 4 in 13 (22%) paƟents.
Right ventricular funcƟon (as judged subjecƟvely on echocardiography, available in
62 paƟents), was moderately or severely diminished in 12 (19%) paƟents. Bileaﬂet
mechanical valves were used in all paƟents, 37 (54%) St. Jude Medical prostheses, 15
(22%) ATS prostheses, 11 (16%) Carbomedics prostheses, 1 (2%) Duromedics prosthesis
and 4 (6%) ON-X prostheses. Mean labeled size of the prostheses was 24.0 ± 1.8
mm. Concomitant cardiac surgery was performed in 37 (54%) paƟents of which most
frequently tricuspid valve annuloplasty (table 2).
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Concomitant surgery* N (%)
Tricuspid valve annuloplasty 19 (29)
Total correcƟon tetralogy of Fallot 1 (2)
Redundant right ventricular muscle band cleavage 1 (2)
Right ventricular trabeculectomy 1 (2)
Atrial septal defect repair 4 (6)
Right atrial reconstrucƟon 1 (2)
Residual ventricular septal defect repair 4 (6)
AorƟc valve replacement 3 (4)
AorƟc valve repair 1 (2)
Para-aorƟc valvar leakage repair 1 (2)
Supracoronary aorta ascendens replacement 1 (2)
Coronary ﬁstula 1 (2)
Mitral valve replacement 3 (4)
Mitral valve repair 1 (2)
Pacemaker 5 (7)
Maze procedure 2 (3)
False retrosternal aneurysm 1 (2)
Persistent leŌ caval vein tunnel reconstrucƟon 1 (2)
Table 2 - Concomitant procedures performed during pulmonary valve replacement procedure.
*: Some paƟents had more than one concomitant procedure.
ComplicaƟons
Eight paƟents (12%) encountered a prosthesis-related complicaƟon which was fatal in
1 paƟent (2%) and necessitated a redo PVR in 6 (9%). Freedom from re-PVR in survivors
was 96% (SE 3%) and 89% (SE 5%) at 5 and 10 years respecƟvely (ﬁgure 1). The incidence
of pulmonary mechanical valve thrombosis was 1.5% paƟents/year.
The eight paƟents with prosthesis-related complicaƟons are described in detail as
follows:
PaƟent 1 was a 39 year old female with a history of Ross procedure aŌer endocardiƟs
of the aorƟc valve. During follow-up, redo aorƟc valve replacement, mitral valve
replacement and redo PVR (St. Jude 23mm) was performed with mechanical valve

















and three previous caesarian secƟons, she became pregnant. She developed valve
thrombosis at 18 weeks pregnancy while being treated with ﬁxed dose low molecular
weight heparin without anƟfactor Xa monitoring.[15] Urokinase and heparin dissolved
the thrombus and did not result in bleeding or other complicaƟons in the paƟent or
fetus.
PaƟent 2was a 42 year old female with ToF. Six months aŌer the iniƟal PVR (St. Jude 23
mm), valve dysfuncƟon caused by valve thrombosis was observed on echocardiography
and cineﬂuoroscopy. The lowest reported INR since the PVR was 2.5. Re-PVR
with a CarpenƟer Edwards bovine pericardial valve was performed aŌer unsuccessful
thrombolysis.
PaƟent 3 was a 37 year old male with repaired ToF. He withdrew from follow-up and
stopped taking acenocoumarol on his own iniƟaƟve. AŌer 2 years of absence he
reappeared with complaints of dyspnea caused by pulmonary valve dysfuncƟon and
segmental pulmonary embolism due to valve thrombosis. He underwent re-PVR with a
bioprosthesis 5 years aŌer his iniƟal PVR (ATS 27mm).
Figure 1 - Freedom from redo PVR following 68 mechanical PVRs in 66 paƟents.
At 2, 4, 6, 8 and 10 years, respecƟvely 54, 39, 27, 18 and 14 paƟents were at risk.
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PaƟent 4 was a 31 year old male with ToF. AŌer inadequate dosing of oral
anƟcoagulaƟon, valve thrombosis led to dysfuncƟon of one valve-leaﬂet (ATS 25
mm). Adequate anƟcoagulaƟon did not dissolve the thrombus. A re-PVR was
performed using a homograŌ 6 years aŌer his iniƟal PVR.
PaƟent 5 was a 47 year old female with pulmonary valve atresia and a ventricular
septal defect. In her tenth year aŌer PVR (St. Jude 23mm) the transvalvular gradient of
the mechanical valve increased rapidly. A redo PVR with a mechanical valve prosthesis
was performed 10 years aŌer her iniƟal PVR. The cardiothoracic surgeon described
a large mass of Ɵssue situated in the right lateral hinge that looked more like an
organized thrombus than pannus. Pathology conﬁrmed the diagnosis of a mix of valve
thrombosis and pannus.
PaƟent 6was a woman with an atrioventricular septal defect and ToF that necessitated
a mechanical PVR (Duromedics 21mm) and a leŌ atrioventricular valve replacement at
the age of 6 years. Thirteen years aŌer the ﬁrst PVR pannus rendered one mechanical
leaﬂet immobile which dictated a re-PVR with a another mechanical prosthesis (St.
Jude 23mm) at the age of 19 years. Nine years later the paƟent required a heart
transplant due to end-stage heart failure, but complicaƟons during the operaƟon
proved fatal.
PaƟent 7 was a 31 year old female with repaired ToF. Eight years aŌer PVR (St.
Jude 23mm) a caesarian secƟon was performed which was complicated by severe
postoperaƟve bleeding. A relaparotomy was performed and unfracƟoned i.v. heparin
(which she used the days before the caesarean secƟon) needed to be disconƟnued for
24 hours. She subsequently developed a dysfuncƟoning mechanical valve prosthesis
due to a valvar thrombus. Because she had a contra-indicaƟon for thrombolysis (high
bleeding risk aŌer recent caesarean secƟon and relaparotomy), she was treated with
redo PVR using a bioprosthesis.
PaƟent 8 was a 36 year old female with a truncus arteriosus that died of pulmonary



















All paƟents survived the iniƟal PVR operaƟon. One paƟent with pulmonary stenosis
died 5 days aŌer the operaƟon due to an ischemic, (probably) embolic, cerebro-vascular
accident, resulƟng in a 30-day mortality of 1.5%. There were 11 late deaths (17%)
observed during a mean follow-up duraƟon of 5.9 ± 4.8 years (median 4.9) including
2 deaths following prosthesis-related complicaƟons. These two paƟents are described
in the ‘complicaƟons’ secƟon and comprise 1 paƟent that died following pulmonary
hemorrhaging (paƟent no. “8”) and 1 paƟent that died of a complicaƟon during heart
transplantaƟon (paƟent no. “6”). A further ﬁve paƟents (8%) died of end-stage heart
failure, 2 (3%) suﬀered a sudden death, 1 paƟent died of sepsis following dialysis
treatment, and 1 paƟent died of the complicaƟons of cardiac carcinoid. Survival aŌer
the ﬁrst mechanical valve prosthesis at 5 years was 91% (SE 4%) and at 10 years 81% (SE
7%), Fig. 2. Concomitant tricuspid valve annuloplasty or tricuspid valve replacement
had been performed in all 12 (100%) of the deceased paƟents compared to only 20% in
survivors.
Figure 2 - Survival of 66 paƟents with mechanical PVRs.
At 2, 4, 6, 8 and 10 years, respecƟvely 53, 38, 27, 18 and 14 paƟents were at risk.
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Commentp
We now present the largest series thus far on mid- and long-term results of PVR using
mechanical valve prostheses. Our early experience with pulmonary mechanical valve
prostheses was promising and the use of mechanical valves was suggested to be a
strategy to prevent future redo PVRs [6]. Other recent studies [6-13], with a total of
almost 240mechanical valve prostheses, also reported promising results with low short-
and midterm rates of re-PVR and valve thrombosis (table 3).
We now report 12% prosthesis-related complicaƟons in paƟents with mechanical valve
prostheses necessitaƟng 9% re-PVRs during a mean follow-up of 6 years. The freedom
from re-PVR rate in paƟents with a mechanical valve prostheses at 5 and 10 years was
96% and 89% respecƟvely, which is comparable to that recently reported for allograŌs
(freedom from re-PVR: 82% to 95% at 5 years and 83% at 10 years) [3,4,16]. The
literature shows that allograŌs in children have a poorer freedom from re-PVR (60%
at 5 years and 50% at 10) due to early graŌ failure [17]. Risk factors for biological
graŌ failure include high pulmonary arterial pressure, small prosthesis size and young
age [16]. The predominant prosthesis-related complicaƟon that necessitated re-PVR
in our cohort was mechanical valve thrombosis of which most cases occurred in the
seƫng of inadequate anƟcoagulaƟon or pregnancy. It is suggested that mechanical
valves in the pulmonary posiƟon have higher rates of valve thrombosis than leŌ-sided
prostheses possibly due to a lower leakage backﬂow velocity related to the relaƟvely
low pressures in the right sided circulaƟon [18]. AnƟcoagulaƟon therapy is therefore
imperaƟve but caries the risk of bleeding complicaƟons. In our series the prevalence
of major bleeding was however low (3%). Important is that even paƟents that correctly
follow a strict anƟcoagulaƟon regiment can face a situaƟon inwhich anƟcoagulaƟon has
to be disconƟnued because of bleeding (i.e. our paƟent 1 with bleeding complicaƟons
aŌer caesarean secƟon).
The long-term survival at 5 and 10-years aŌer a mechanical PVR was 91% and 81%
respecƟvely which is lower than the reported survival in paƟents with pulmonary
bioprostheses (95% to 98% at 5 years and 91% at 10 years) [3,4]. In this study a
selecƟon bias is present as paƟents with more advanced ventricular disease were more
likely to receive a mechanical valve prosthesis than a biological prosthesis in order
to prevent future re-PVR. PaƟents that died of heart failure or sudden death all had
their PVR before 2001 when Ɵming of the PVR was not guided by magneƟc resonance

















tricuspid valve repair, the right ventricle may already have been irreversibly dilated and
dysfuncƟonal in these cases. Three paƟents that died of heart failure already had clinical
episodes of right heart failure before PVR.
The main advantage of mechanical valve prostheses compared to biological valve
prostheses should be the durability, which is of especial importance in paƟents with
a high surgical risk for instance because of a history of mulƟple sternotomies with risks
of adhesions [19]. However, in our study the redo PVR rates of mechanical prostheses
are comparable to those in biological prostheses. The evoluƟon of transcatheter valve
replacements will reduce the number of open heart surgeries in failing bioprostheses,
but may increase the risk of paƟent-prosthesis mismatch and deterioraƟon of the
biological transcatheter valve will eventually sƟll lead to the necessity for re-operaƟon.
Inmany paƟents the primary choice for a pulmonary valve prosthesis will be a biological
valve. Based on our own, as well as previously reported series, we believe that
there is a subpopulaƟon of paƟents in whom mechanical valves may outperform
bioprostheses. Our current policy is to avoid implantaƟon of a mechanical valve
in the pulmonary posiƟon in paƟents in whom the risk of noncompliance with
anƟcoagulaƟon therapy is foreseen, in young women of ferƟle age who may wish
to become pregnant in the future, in paƟents who may need future re-intervenƟon
for pulmonary arterial stenoses, or paƟents who have a (relaƟve) contra-indicaƟon
for anƟcoagulaƟon therapy [5,15]. Suitable candidates for a mechanical PVR are in
our view paƟents with a high risk of biological valve deterioraƟon (such as paƟents
with high pulmonary artery pressures), paƟents who already have an indicaƟon for
permanent anƟcoagulaƟon therapy, and paƟents with a high re-operaƟon risk (i.e.
mulƟple previous sternotomies), especially when the size of the pulmonary annulus
would prevent future transcatheter valve-in-valve implantaƟon. However, it is of great
importance to assess the thrombo-embolic and bleeding risks before implanƟng a
mechanical valve prosthesis and to create awareness in the paƟent that incorrect INR
levels can lead to severe complicaƟons including bleeding complicaƟons or redo PVR
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